Back to today’s briefing

Story perspectives

Axsome Therapeutics Projects Loss Amid Optimistic Analyst Ratings

2/16/2025

49 11

Summary

Story summary

Axsome Therapeutics is gearing up to reveal its earnings on February 18, projecting a loss of $0.97 per share alongside anticipated revenue of $117.83 million. Analysts are optimistic, holding a "Moderate Buy" rating with a target price of $147.13. Recent trading insights recommend buying at $111.41 or $138.17, with defined stop-loss levels for investors.

1 of 1

Story summary

Axsome Therapeutics is gearing up to reveal its earnings on February 18, projecting a loss of $0.97 per share alongside anticipated revenue of $117.83 million. Analysts are optimistic, holding a "Moderate Buy" rating with a target price of $147.13. Recent trading insights recommend buying at $111.41 or $138.17, with defined stop-loss levels for investors.